首页
生知快讯
技术天地
技术新突破
期刊应用实例
技术发展方向
文献视角
Biomarker研究
细胞生物学
基因组生物学
分子生物学
行业速报
行业新资讯
上下游动态
产业新趋势
文献园地
文献库
期刊库
文献重点解析
品牌库
全球科研基金查询
科研学者库
登录/注册
首页
>
期刊库
>
期刊详情
Mol Cancer Ther
收藏
期刊全称
Mol Cancer Ther
注:上述信息均来源于网络,仅供查考,如有遗漏或信息错误,欢迎
向我反馈
。
期刊相关文献 (201)
Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia
靶向SUMO化可触发急性髓系白血病临床前模型中患者和同种异体NK细胞的IFN-β依赖性活化。
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC7618005
Rawan Hallal,Marion de Toledo,Denis Tempé,Rayane Berrahouane,Sara Zemiti,Loïs Coënon,Delphine Gitenay,Simon George,Moritz Schüssler,Nadine Laguette,Sarah Bonnet,Ludovic Gabellier,Guillaume Cartron,Mireia Pelegrin,Martin Villalba,Guillaume Bossis
白血病
细胞生物学
IFN-β
SUMO
HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with Irradiation
HPV和p53状态作为头颈癌对DNA-PKcs抑制剂联合放射治疗反应的精确决定因素
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC11791480
Liana Hayrapetyan ,Selina M Roth ,Aurélie Quintin,Lusine Hovhannisyan ,Matúš Medo,Rahel Riedo,Julien G Ott,Joachim Albers,Daniel M Aebersold,Yitzhak Zimmer,Michaela Medová
头颈癌
肿瘤
P53
PKC
DNA-PKcs
Depleting the Action of EZH2 through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
通过抑制PI3K-mTOR通路来减弱EZH2的活性,从而克服三阴性乳腺癌的转移和免疫治疗耐药性
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12485387
Michelle Melino #,Wen Juan Tu #,Helle Bielefeldt-Ohmann,Martina Proctor,Taniya Ahuja,John Vandermeide,Amanda L Bain,Gahyathiri Nallan,Sal Lee Goh,Thiru Prasanna,Jane E Dahlstrom,Mariska Miranda,Ramesh Kumar Chaudhary,Aravind Anandam,Sumit Chaudhary,Jonathan T Seal,Debottam Sinha,Shaoqian Zhang,Tam Hong Nguyen,Sriganesh Srihari,Gunter Hartel,Amy Ives,Laeeq Malik,Desmond Yip,Michelle Nottage,Melissa Eastgate,Sudha Rao
乳腺癌
信号转导
肿瘤
免疫/内分泌
MTOR
EZH2
mTOR
Macrophage-Engaging IgG4 Antibody Triggers Cytotoxicity Against Integrin αvβ3+ Cancers
巨噬细胞结合IgG4抗体触发针对整合素αvβ3+癌细胞的细胞毒性
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12570272
Joshua P Reddy,Ziqi Yu,Ryan M Shepard,Tami Von Schalscha,Rebecca A Clague,Beatriz P Peixoto,Stephen J McCormack,Mark W Onaitis,Sara M Weis,David A Cheresh,Hiromi I Wettersten
细胞生物学
毒理研究
肿瘤
巨噬细胞
IgG
巨噬细胞
A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
一种新型B7-H4xCD3双特异性T细胞衔接剂(PF-07260437)与乳腺癌标准疗法和免疫检查点疗法具有协同作用
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12214883
Keith Abayasiriwardana #,Lei Wu #,Hanane Laklai #,Malgorzata Nocula-Lugowska,Lioudmila Tchistiakova,Jatin Narula,Amy Jackson-Fisher,Jonathon Golas,My-Hanh Lam,Veronika Grinstein,Jung Wook Kang,Jessica C Kearney,Christine Hosselet,Erik Upeslacis,LuAnna Lemon,Yun Zhang,Changhua Ji,Bernard S Buetow,Martin B Finkelstein,Netonia Marshall,Stephanie Bisulco,Edward Rosfjord,Divya Mathur,Jennifer Athanacio,Ashley Thomas,Alexander Trageser,Diane Fernandez,Ziyue Karen Jiang,Sripad Ram,Edward Cabral,Lisa Manzuk,Kevin Maresca,Anand Giddabasappa,Clare Lees,Andrea T Hooper,Puja Sapra,Sudhakar Chintharlapalli
乳腺癌
细胞生物学
肿瘤
免疫/内分泌
T细胞
CD3
Checkpoint
T细胞
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
泛KRAS抑制剂BI-2493和BI-2865在KRAS野生型等位基因扩增的肿瘤中显示出强大的抗肿瘤活性
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC11962398
Antonio Tedeschi #,Fiorella Schischlik #,Francesca Rocchetti #,Johannes Popow,Florian Ebner,Daniel Gerlach,Antonia Geyer,Valeria Santoro,Andrew S Boghossian,Matthew G Rees,Melissa M Ronan,Jennifer A Roth,Jesse Lipp,Matthias Samwer,Michael Gmachl,Norbert Kraut,Mark Pearson,Dorothea Rudolph
肿瘤
RAS
Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
开发一种新型双功能抗CD47融合蛋白,该蛋白具有更高的疗效和良好的安全性。
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12134747
Sittana Matar,Seham Skah,Liza E Diomande,Tim Buss,Hanne R Hagland,Ajay Yadav,Rune J Forstrøm,Bjørn Dalhus,Kjetil Hestdal,Rolf D Pettersen,Nina Richartz
CD4
CD47
Antineoplastic Activity of a Novel Trispecific Single-Chain Antibody Targeting the hERG1/β1 Integrin Complex and TRAIL Receptors
一种靶向hERG1/β1整合素复合物和TRAIL受体的新型三特异性单链抗体的抗肿瘤活性
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12485380
Claudia Duranti ,Jessica Iorio,Chiara Capitani,Tiziano Lottini,Michele Martinelli,Julia Roosz,Nicole Anderle,Tengku Ibrahim Maulana,Peter M Loskill,Rossella Colasurdo,Cesare Sala,Lara Magni,Annarosa Arcangeli
肿瘤
ERG
ERG1
TRAIL
Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis
WAY262611通过抑制DKK-1抑制骨肉瘤转移
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12048250
Adit Tal,Shimara Gunawardana-Zeigler ,Da Peng,Yuqi Tan,Natalia Munoz Perez,Rachel Offenbacher,Laurel Kastner,Paul Ciero,Matthew E Randolph ,Yun Gong,Hong-Wen Deng,Patrick Cahan,David M Loeb
骨肉瘤
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits
基于DDR通路缺陷的原位GBM PDX模型中DNA-PK抑制剂显示出不同的放射增敏作用
期刊:
Mol Cancer Ther
影响因子:
5.300
doi:
PMC12014860
Sonja Dragojevic,Emily J Smith,Michael S Regan,Sylwia A Stopka,Gerard Baquer,Zhiyi Xue,Wenjuan Zhang,Margaret A Connors,Jake A Kloeber,Zeng Hu,Katrina K Bakken,Lauren L Ott,Brett L Carlson,Danielle M Burgenske,Paul A Decker,Shulan Tian,Shiv K Gupta,Daniel J Laverty,Jeanette E Eckel-Passow,William F Elmquist,Nathalie Y R Agar,Zachary D Nagel,Jann N Sarkaria,Cameron M Callaghan
信号转导
1
2
3
4
5
6
21